Recent Finacing
Recent Raise
Escient Pharmaceuticals is a clinical-stage company developing oral small-molecule MRGPR antagonists (EP262 targeting MRGPRX2; EP547 targeting MRGPRX4) to treat urticarias, atopic dermatitis and cholestatic pruritus.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Escient Pharmaceuticals.
